Table 1.
Clinical findings of 51 cases of MTX-LPD in the oral cavity and 84 in the whole body.
| Oral cavity | Whole body | |
|---|---|---|
| No. of cases | 51 | 84 |
| Age | ||
| Median (range) | 70.2 (40–87) | 67.6 (34–87) |
| Sex | ||
| Male | 14 (27.5%) | 24 (28.6%) |
| Female | 37 (72.5%) | 60 (71.4%) |
| MTX administration | 2.5 | |
| Dose (mg/week), median (range) | 7.26 (2.0–15.5) | 5.84 (4.0–8.0) |
| Duration (month), median (range) | 99.0 (1–360) | 56.7 (2–193) |
| Autoimmune disease | ||
| Rheumatoid arthritis | 50 (98.0%) | 36 (100%) |
| Others | 1 (2.0%) | 5 (SS, SLE, PMR) |
| Duration (month), median (range) | 142.8 (6–396) | 105.5 (27–360) |
| Primary site | ||
| Gingiva | 39 (76.5%) | |
| Tongue | 6 (11.8%) | |
| Mouth floor | 2 (3.9%) | |
| Plate | 2 (3.9%) | |
| Others | 2 (3.9%) | |
| Multiple sites | ||
| (+) | 11 (21.6%) | 70 (83.3%) |
| Oral | 5 | |
| Others (lung and liver) | 6 | |
| (−) | 40 (78.4%) | 12 (14.3%) |
| EBV infection | ||
| (+) | 49 (96.1%) | 25 (29.8%) |
| (−) | 1 (2.0%) | 51 (60.7%) |
| Unknown | 1 (2.0%) | 8 (9.5%) |
| Histopathological diagnosis | ||
| DLBCL | 38 (74.5%) | 52 (61.9%) |
| Hodgkin's lymphoma | 6 (11.8%) | 14 (16.7%) |
| Others | 7 (13.7%) | 18 (21.5%) |
| Treatment | ||
| W | 39 (76.5%) | 33 (39.3%) |
| C | 5 (9.8%) | 41 (48.8%) |
| W⟶C | 4 (7.8%) | 4 (4.8%) |
| Others | 3 (5.9%) | 6 (7.1%) |
| Recurrence | ||
| (+) | 2 (3.9%) | 19 (22.6%) |
| (−) | 40 (78.4%) | 59 (70.2%) |
| Unknown | 9 (17.6%) | 6 (7.2%) |
MTX, methotrexate; SS, Sjogren's syndrome; SLE, systemic lupus erythematosus; PMR, polymyalgia rheumatica EBV, Epstein-Barr virus; DLBCL, diffuse large B-cell lymphoma; W, withdrawal of MTX; C, chemotherapy